Flare-up of adult-onset Still's disease after receiving a second dose of BNT162b2 COVID-19 mRNA vaccine

Clin Exp Rheumatol. 2021 Sep-Oct;39 Suppl 132(5):139-140. doi: 10.55563/clinexprheumatol/tvlpnc. Epub 2021 Oct 6.

Authors

Shintaro Yamamoto¹, Keisuke Nishimura², Kohei Yo¹, Daisuke Waki¹, Hiroyuki Murabe¹, Toshihiko Yokota¹

Affiliations

¹ Department of Endocrinology and Rheumatology, Kurashiki Central Hospital, Okayama, Japan.
² Department of Endocrinology and Rheumatology, Kurashiki Central Hospital, Okayama, Japan. keinishi@med.kobe-u.ac.jp.

PMID: 34622765
DOI: 10.55563/clinexprheumatol/tvlpnc

No abstract available

Publication types

Letter

MeSH terms

Adult
BNT162 Vaccine
COVID-19 Vaccines
COVID-19*
Humans
RNA, Messenger
SARS-CoV-2
Still's Disease, Adult-Onset* / diagnosis
Still's Disease, Adult-Onset* / drug therapy

Substances

COVID-19 Vaccines
RNA, Messenger
BNT162 Vaccine